COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Protocol No
JOUNCE-JTX-8064-101
Principal Investigator
Deepak Kilari
Phase
I
Summary
This project is being done to find out what dose is safe and tolerable, what effects, both good and bad when given by itself or in combination with JTX-4014, Keytruda or Libtayo. How much JTX-8064 gets into the bloodstream, and how long for the body to get rid of it.
Description
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL